NCT02269605

Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment

Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trial´s goal is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral treatment.

Conditions

• HIV Infection

Interventions

Type	Name	Description
OTHER	Placebo	Group 1: Placebo (sodium chloride 0.8 %) at single dose
DRUG	Bryostatin 1 (10ug/m2)	Group 2: Bryostatin 1 (10ug/m2) at single dose
DRUG	Bryostatin 1 (20ug/m2)	Group 3: Bryostatin 1 (20ug/m2) at single dose

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-01-01
• Completion: 2015-12-01
• First posted: 2014-10-21
• Last updated: 2015-12-18

Locations

1 site across 1 country: Spain